CDC Warns of 'Rhino Tranq' Infiltrating Illicit Drug Supply

The animal sedative medetomidine has been linked to severe withdrawal symptoms that do not respond to standard opioid treatment.

Apr. 7, 2026 at 8:05am

Got story updates? Submit your updates here. ›

A translucent, ghostly X-ray photograph showing the internal structure of a syringe filled with a glowing, ethereal liquid substance, representing the clinical and anatomical nature of the 'rhino tranq' drug crisis.An X-ray image reveals the ghostly internal structure of a syringe containing the potent animal sedative medetomidine, which has infiltrated the illicit drug supply.St. Petersburg Today

The CDC and White House Office of National Drug Control Policy have issued a health alert warning clinicians about the growing presence of the animal sedative medetomidine, known as 'rhino tranq,' in the illicit drug supply, particularly mixed with fentanyl. Medetomidine has been associated with a severe withdrawal syndrome that does not appear to respond to conventional opioid withdrawal treatment.

Why it matters

The emergence of medetomidine in the illicit drug market poses significant public health risks, as the sedative can cause life-threatening withdrawal symptoms that are difficult to manage. This development highlights the ongoing challenges in addressing the opioid crisis and the need for enhanced monitoring and response strategies to protect vulnerable populations.

The details

Medetomidine, which is used to sedate dogs, is not approved for human use, but its dextro isomer, dexmedetomidine, is approved for procedural sedation in humans. The CDC believes the medetomidine is being purposefully introduced into the illicit supply, as preservatives commonly found in medical or veterinary formulations have not been detected. Medetomidine was first detected in the US in 2021, appearing sporadically with fentanyl in the illicit drug supply in Chicago, Philadelphia, and Pittsburgh. Since then, the substance has been increasingly detected in law enforcement drug seizures, with reports to the National Forensic Laboratory Information System increasing by 950% between 2023 and 2024 and another 250% in 2025.

  • Medetomidine was first detected in the US in 2021.
  • Between 2023 and 2024, reports of medetomidine to the National Forensic Laboratory Information System increased by 950%.
  • In 2025, reports of medetomidine to the National Forensic Laboratory Information System increased by another 250%.
  • Between October 2025 and January 2026, medetomidine was found in wastewater every week in at least 1 of 14 states that participate in a wastewater testing program.

The players

CDC

The Centers for Disease Control and Prevention, a leading national public health institute in the United States.

White House Office of National Drug Control Policy

A component of the Executive Office of the President of the United States that sets and coordinates drug control policies.

University of North Carolina's Street Drug Analysis Lab

A laboratory that analyzes samples of illicit drugs to identify emerging substances in the drug supply.

Got photos? Submit your photos here. ›

What’s next

The CDC alert provides clinicians with guidance on managing medetomidine withdrawal, including the use of opioid withdrawal protocols, alpha-2 agonist therapy, and hypertension management. Continued monitoring and reporting of medetomidine in the illicit drug supply will be crucial to understanding the scope of the issue and developing effective interventions.

The takeaway

The emergence of medetomidine, a potent animal sedative, in the illicit drug supply poses a significant public health threat, as it can cause severe and potentially life-threatening withdrawal symptoms that do not respond to standard opioid treatment. This development underscores the ongoing challenges in addressing the opioid crisis and the need for enhanced surveillance, education, and harm reduction strategies to protect vulnerable populations.